Assembly Biosciences (ASMB) Debt to Equity (2010 - 2011)

Assembly Biosciences (ASMB) recorded quarterly Debt to Equity of $0.14 in Q2 2011, down 3.77% quarter-over-quarter from $0.15 in Q4 2010.

Assembly Biosciences (ASMB) Debt to Equity (2010 - 2011) Analysis & Trends

Assembly Biosciences' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.14 for Q2 2011.

  • In Q2 2011, Debt to Equity changed N/A year-over-year to $0.14; the TTM figure through Jun 2011 stood at $0.14 (changed N/A YoY), while the FY2010 annual figure was $0.15, changed N/A from the prior year.
  • Debt to Equity was $0.14 for Q2 2011 at Assembly Biosciences, down from $0.15 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.15 in Q4 2010 to a low of $0.14 in Q2 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 0.32
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Assembly Biosciences 418.96 Mn 192.36 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2011 0.14
Dec 31, 2010 0.15